ArticleJBMR plus2019

First-in-Asian Phase I Study of the Anti-Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X-linked Hypophosphatemia.

Hae Il Cheong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.